Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 2
2002 1
2003 3
2004 1
2006 4
2007 1
2008 3
2009 1
2010 2
2011 4
2012 2
2013 3
2014 2
2015 3
2016 5
2017 1
2018 1
2019 3
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.
Lopatin YM, Rosano GM, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LH, Vinereanu D, Hamid MA, Jourdain P, Ponikowski P. Lopatin YM, et al. Int J Cardiol. 2016 Jan 15;203:909-15. doi: 10.1016/j.ijcard.2015.11.060. Epub 2015 Nov 7. Int J Cardiol. 2016. PMID: 26618252 Review.
Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. ...This review focuses on th …
Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing g …
Energy Remodeling, Mitochondrial Disorder and Heart Failure.
Wang P, Xu L, Sun A. Wang P, et al. Curr Pharm Des. 2016;22(31):4823-4829. doi: 10.2174/1381612822666160708224330. Curr Pharm Des. 2016. PMID: 27396599 Review.
Heart failure (HF) is a major global problem in public health with no curative treatment currently available. Energy remodeling is one of the features in HF, preceding cardiac structure remodeling. ...It also highlights the potentials of novel drugs ta
Heart failure (HF) is a major global problem in public health with no curative treatment currently available. Energy re
Trimetazidine in cardiovascular medicine.
Marzilli M, Vinereanu D, Lopaschuk G, Chen Y, Dalal JJ, Danchin N, Etriby E, Ferrari R, Gowdak LH, Lopatin Y, Milicic D, Parkhomenko A, Pinto F, Ponikowski P, Seferovic P, Rosano GMC. Marzilli M, et al. Int J Cardiol. 2019 Oct 15;293:39-44. doi: 10.1016/j.ijcard.2019.05.063. Epub 2019 May 24. Int J Cardiol. 2019. PMID: 31178223 Review.
Abnormalities of myocardial energy metabolism appear as a common background of the two major cardiac disorders: ischemic heart disease (IHD) and heart failure (HF). ...For these reasons, several studies have explored the potential benefit …
Abnormalities of myocardial energy metabolism appear as a common background of the two major cardiac disorders: ischemi …
Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.
Fragasso G. Fragasso G. Card Fail Rev. 2016 May;2(1):8-13. doi: 10.15420/cfr.2016:5:2. Card Fail Rev. 2016. PMID: 28785448 Free PMC article.
In this context, manipulation of cardiac energy metabolism by modification of substrate use by the failing heart has produced positive clinical results. The results of current research support the concept that shifting the energy substrate prefe …
In this context, manipulation of cardiac energy metabolism by modification of substrate use by the failing heart
Metabolic Modulation of Cardiac Metabolism in Heart Failure.
Rosano GM, Vitale C. Rosano GM, et al. Card Fail Rev. 2018 Aug;4(2):99-103. doi: 10.15420/cfr.2018.18.2. Card Fail Rev. 2018. PMID: 30206484 Free PMC article. Review.
Heart failure (HF) is associated with metabolic changes that cause a progressive impairment of cardiac and skeletal muscle high-energy phosphate production. As a consequence of the impaired cardiac metabolism, other processes are activate
Heart failure (HF) is associated with metabolic changes that cause a progressive impairment of cardiac and skeletal mus
Metabolic support for the heart: complementary therapy for heart failure?
Heggermont WA, Papageorgiou AP, Heymans S, van Bilsen M. Heggermont WA, et al. Eur J Heart Fail. 2016 Dec;18(12):1420-1429. doi: 10.1002/ejhf.678. Epub 2016 Nov 4. Eur J Heart Fail. 2016. PMID: 27813339 Free article. Review.
Therefore, therapies targeting the energy-deprived failing heart and rewiring cardiac metabolism are of great potential, but are lacking in daily clinical practice. ...In this review, we discuss the hallmarks of normal cardiac metabolism, …
Therefore, therapies targeting the energy-deprived failing heart and rewiring cardiac metabolism are of great po …
A network pharmacology approach to discover action mechanisms of Yangxinshi Tablet for improving energy metabolism in chronic ischemic heart failure.
Wu RM, Jiang B, Li H, Dang WZ, Bao WL, Li HD, Ye G, Shen X. Wu RM, et al. J Ethnopharmacol. 2020 Jan 10;246:112227. doi: 10.1016/j.jep.2019.112227. Epub 2019 Sep 8. J Ethnopharmacol. 2020. PMID: 31509780
AIM OF STUDY: Active ingredients and potential targets of YXS for treating heart failure have been reported previously. However, the molecular functions or biological processes of YXS in energy metabolism have not been discovered. ...The cardiac
AIM OF STUDY: Active ingredients and potential targets of YXS for treating heart failure have been reported previously. Howeve …
Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
Coats CJ, Pavlou M, Watkinson OT, Protonotarios A, Moss L, Hyland R, Rantell K, Pantazis AA, Tome M, McKenna WJ, Frenneaux MP, Omar R, Elliott PM. Coats CJ, et al. JAMA Cardiol. 2019 Mar 1;4(3):230-235. doi: 10.1001/jamacardio.2018.4847. JAMA Cardiol. 2019. PMID: 30725091 Free PMC article. Clinical Trial.
IMPORTANCE: Hypertrophic cardiomyopathy causes limiting symptoms in patients, mediated partly through inefficient myocardial energy use. ...Secondary end points were 6-minute walk distance, quality of life (Minnesota Living with Heart Failure questionnaire), …
IMPORTANCE: Hypertrophic cardiomyopathy causes limiting symptoms in patients, mediated partly through inefficient myocardial energy u …
Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure.
Lopaschuk GD. Lopaschuk GD. Semin Cardiothorac Vasc Anesth. 2006 Sep;10(3):228-30. doi: 10.1177/1089253206291150. Semin Cardiothorac Vasc Anesth. 2006. PMID: 16959756
Therefore, new treatments are needed for heart failure that work independently of mechanisms already targeted. Emerging evidence suggests that the failure of the myocardium in heart failure is affected by alterations in the energy substra …
Therefore, new treatments are needed for heart failure that work independently of mechanisms already targeted. Emerging eviden …
Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, Ragogna F, Arioli F, Bassanelli G, Spoladore R, Luzi L, Margonato A, Perseghin G. Fragasso G, et al. Heart. 2011 Sep;97(18):1495-500. doi: 10.1136/hrt.2011.226332. Epub 2011 Jun 23. Heart. 2011. PMID: 21700755 Clinical Trial.
OBJECTIVE: Trimetazidine may have beneficial effects on left ventricular (LV) function in patients with systolic heart failure. The authors assessed whether long-term addition of trimetazidine to conventional treatment could improve, along with LV func …
OBJECTIVE: Trimetazidine may have beneficial effects on left ventricular (LV) function in patients with systolic heart fail
43 results
Jump to page
Feedback